Human antibody molecules for IL-13

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9856317
SERIAL NO

15058612

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MEDIMMUNE LIMITEDMILSTEIN BUILDING GRANTA PARK CAMBRIDGE CB21 6GH UNITED KINGDOM

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Jermutus, Lutz Cambridge, GB 21 119
Minter, Ralph Raymond Cambridge, GB 19 84
Monk, Phillip David Cambridge, GB 9 45
Shorrock, Celia Patricia Noyarey, FR 9 105

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 2, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 2, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00